Prevalence of pigmentary disorders: A cross-sectional study in public hospitals in Durban, South Africa

Ncoza C. Dlova, MBChB, FCDerm, PhD a,⇑, Lisa O. Akintilo, MD, MPH b, Susan C. Taylor, MD c

a Department of Dermatology, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
b Department of Medicine, NorthShore University HealthSystem, University of Chicago, Evanston, Illinois
c Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Article info

Article history:
Received 19 December 2018
Received in revised form 23 June 2019
Accepted 7 July 2019

Keywords:
African
dark
dyschromia
dyspigmentation
ethnic skin
Indian
pigmentation
skin of color
South Africa

Abstract

Background: Pigmentary disorders are common in patients with skin of color and one of the top five most common dermatologic diagnoses in individuals of African descent. Little is known about the spectrum of pigmentary disorders in South Africa’s second largest province, KwaZulu Natal.

Objective: This study aimed to determine the profile of pigmentary disorders in patients at five outpatient public hospital skin clinics in Durban, South Africa.

Methods: We collected data related to age, sex, ethnicity, and skin dyspigmentation diagnosis in a cross-sectional descriptive study of all dermatology patients at five public hospitals in Durban, South Africa between January 1 and March 31, 2015. The diagnosis was made on the basis of clinical grounds, supported by relevant laboratory investigations or histopathology where necessary. Only data relating to patients’ first visit were recorded and captured using a Microsoft Excel 2007 spreadsheet.

Results: A total of 304 patients, the majority of whom were African women (n = 230; 75.8%), were included in the study. The three most common pigmentary diagnoses included vitiligo, postinflammatory hyperpigmentation, and melasma.

Conclusion: Dyschromias are the third most common dermatologic diagnosis in Durban, KwaZulu-Natal province, South Africa. The most common subtypes of pigmentary disorders include (in order of frequency) vitiligo, postinflammatory hyperpigmentation, and melasma.

© 2019 Published by Elsevier Inc. on behalf of Women’s Dermatologic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Disorders of pigmentation are commonly seen in dermatology, both in the public and private sector, and may negatively affect patients’ quality of life. Pigmentary disorders represent one of the top five most common dermatologic conditions diagnosed in Africans and African-Americans (Alexis et al., 2007; Dlova et al., 2015b; Halder and Nootheti, 2003). Many studies have been published on the spectrum and prevalence of pigmentary disorders in the Western hemisphere, but little is known about the spectrum of pigmentary disorders in South Africa’s second most populous province, KwaZulu Natal.

The increasing significance of pigmentary disorders worldwide led us to prospectively describe the epidemiology of pigmentary disorders in five major referral public hospitals in Durban, the third most populous city in South Africa and the largest city in the province of KwaZulu Natal. Durban is uniquely situated to study pigmentary disorder rates due to its unique racial profile: 51% of the population is black African, 25% is South Asian, 15% is white, and 9% is of mixed race.

This assessment of pigmentary disorders will assist in the future planning and delivery of limited health care resources by focusing dermatology and public health attention on the most common dyschromias. In doing so, dyschromias may be prevented or treated early to limit progression. Data gathered as part of this study will also allow for continued public health focus on the use of illicit skin bleaching creams, which are commonly used to treat some dyschromias (Dlova et al., 2015a).

Methods

Ethical approval for this study was obtained from the Biomedical Research Ethics Committee of the University of KwaZulu-Natal. A total of 304 patients of primarily African and Indian descent (based on patient self identification) were consecutively enrolled.
into the study out of 3814 dermatology patients seen at five large public health hospitals over a 3-month period. Written informed consent was obtained. The data were entered and analyzed using Microsoft Excel 2007.

This was a cross-sectional descriptive study conducted over a 3-month period. Data were collected using a piloted questionnaire completed by examining doctors after patient consultation. The questionnaire included basic demographics, presenting complaint, HIV status, and specific dermatologic disorder. Only patients who presented with new skin complaints were selected to avoid bias from prior diagnoses. If the diagnosis was unclear at first visit, a skin biopsy was performed and the patient followed up within the study period to confirm the captured diagnosis.

Results

Out of 3814 patients seen over a 3-month period, 304 patients (7.97%) were diagnosed with pigmentedary disorders (frequency of disease previously published as Table 1 in Dlova et al., 2018). Of these 304 patients, 79.6% (n = 242) were adults (>18 years) and 20.4% (n = 62) were children. The majority of patients were female (n = 229; 75.8%), and all patients aged <18 years were students. Fifty percent of the adults (n = 121) were unemployed or housewives, and the remainder were teachers (n = 24; 10%), nurses (n = 19; 8%), domestic workers (n = 73; 30%), and students (n = 5; 2%). With regard to ethnicity, 73.3% of patients (n = 222) were black African, 21.8% (n = 66) were Indian, 2.6% (n = 8) were white, and 2.3% (n = 7) were of mixed race. Of these patients, 13.0% (n = 29) were HIV positive, and the majority were Fitzpatrick phototype 4 to 6. The demographic data are listed in Table 1.

Vitiligo was the most frequently observed dyschromia during the study period (n = 118: 3.09%). Other subtypes of dyschromia diagnosed during the study period included postinflammatory hyperpigmentation (PIH; n = 60; 1.6%) and melasma (n = 24; 0.6%). Ochronosis was diagnosed in 10 cases (0.3%). Figure 1 shows the spectrum of dyschromia diagnoses over the study period.

Discussion

Generally, pigmentedary disorders are common in patients with skin of color. Moreover, the increased visibility within this population often causes significant psychological distress (Davis and Callender, 2010). Dyschromias are the third most common dermatologic diagnosis in Durban, KwaZulu-Natal, (after acne and eczematous eruptions) with an estimated prevalence in the published literature of 11.6% (Dlova et al., 2018). Our study determined an estimated prevalence of 8.0% in a hospital clinic population, which is similar to the data in research conducted in other countries with a large population of patients with skin of color (Dunwell and Rose, 2003; Ogunbiyi et al., 2004; Yahya, 2007).

A Nigerian epidemiologic study estimated the frequency of pigmentedary skin disorders to be 8.6% (Ogunbiyi et al., 2004). A study in the United Arab Emirates documented a 5.4% frequency of pigmentedary disorders (Abu Share'ah and Abdel Dayem, 1991), and research from Saudi Arabia showed a frequency of 9.7% (Alakloby, 2005). Other studies have shown higher frequency rates, with a Jamaican study estimating the prevalence of pigmentedary disorders to be 16.6% (Dunwell and Rose, 2003). A U.S. study of black patients found that dyschromias (not including vitiligo) were diagnosed with a frequency of 19.9% (Alexis et al., 2007). Comparatively, in a survey study of a U.S. sample of white patients, dyschromias were not even listed in the top10 dermatologic diagnoses (Dlova et al., 2015b).

A total of 3.1% of patients in the study sample (n = 118) were diagnosed with vitiligo, which was the most common dermatologic diagnosis in the present study. Of note, the current percentage is less than the prevalence of 5.7% estimated in a 2004 Nigerian epidemiologic study (Ogunbiyi et al., 2004). In another study of patients with skin of color, a Michigan study of Arab-Americans showed a frequency of vitiligo of 2.0% (El-Essawi et al., 2007). Of note, a 2016 meta-analysis showed that vitiligo rates are higher in African countries than anywhere else in the world (Zhang et al., 2016). This is consistent with a 2015 study that found that vitiligo occurred significantly more often in black patients within the African continent compared with those in North America (Dlova et al., 2015b).

Within our sample, 1.57% of patients were diagnosed with PIH. Comparatively, a 2003 U.S. study demonstrated a PIH prevalence of 9% in African Americans (Halder and Noothethi, 2003). A 2003 Jamaican study reported a 16.6% estimated prevalence of dyschromias, with >50% of dyschromias attributable to PIH (Dunwell and Rose, 2003). Similarly to vitiligo, the increased visibility of PIH in patients with higher Fitzpatrick skin types leads to frequent dermatology visits, decreased self-image, and diminished quality of life (Davis and Callender, 2010).

Melasma is described as symmetric grey-brown hyperpigmentation, typically on the face, that is frequently seen in patients with skin of color, particularly women. A total of 0.6% of patients in our study were diagnosed with melasma. General estimations of global melasma prevalence rates range from 1% in the general population to 9% to 50% in at-risk populations. Risk factors include pregnancy, ultraviolet ray exposure, and darker skin phenotype (Ogbecbie-Godec and Elbuluk, 2017). The melasma prevalence rate of 0.6% is much less than figures documented in other research studies in other countries. This could be because melasma can be considered a cosmetic skin condition like PIH and most public hospitals do not offer treatment for melasma. In a 2015 study of 6600 participants by Dlova et al. (2015b) in the same province but in the private sector, the prevalence of melasma was 4%.

Research in Ethiopia showed a 1.5% prevalence of melasma (Hiletework, 1998). In addition, a melasma study in Saudi Arabia found a prevalence of 2.9% (Parthasaradhi and Al Gufai, 1998), but an Arab-American population was found to have a melasma prevalence of 14.5% (El-Essawi et al., 2007). One study found that men represent only 10% of the melasma population, incidentally with low-testosterone documented in this group (Awosika et al., 2017; Sarkar et al., 2010).

Table 1
Frequency of pigmentation disorders by participant characteristics

|          | Number | Percentage |
|----------|--------|------------|
| Population |        |            |
| Adult (>18 years) | 242 | 79.6 |
| Pediatric (<18 years) | 62 | 20.4 |
| Total | 304 | 100 |
| Sex | | |
| Female | 229 | 75.8 |
| Male | 73 | 24.2 |
| Total | 302 | 100 |
| Ethnicity | | |
| African | 222 | 73.3 |
| Indian | 66 | 21.8 |
| White | 8 | 2.6 |
| Mixed race | 7 | 2.3 |
| Total | 303 | 100 |
| HIV status (4 hospitals only) | | |
| Positive | 29 | 13.0 |
| Negative | 194 | 87.0 |
| Total | 223 | 100 |
Although exogenous ochronosis is a result of inappropriate and long-term use of hydroquinone, it presents with nonmelanin dyschromia. We would like to pay special attention to exogenous ochronosis because of its relevance in the South African dermatology landscape. Ochronosis appears as blue-black pigmented deposits that are most frequently found on the face after use of skin-lightening agents, such as corticosteroids, mercury, or hydroquinone. Although not a disorder of pigmentation, the appearance of ochronosis as a complication of treatment or self-initiated skin-lightening regimens can be quite worrisome to patients and prompt a dermatology consultation.

Ochronosis is quite a rare diagnosis in the United States (Vashi and Kundu, 2013). A 2006 literature review found that, out of 789 documented worldwide cases, only 22 diagnoses were made in the United States (Levitt, 2007). Ochronosis was the least frequent dermatologic diagnosis in the Durban study sample, with a rate of 0.3%. Other countries with large populations with skin of color, such as Ghana, have been shown to have higher rates of exogenous ochronosis—one study showed a frequency of 0.9% (Doe et al., 2001). Interestingly, a 1989 study found that, within a sample of patients visiting a dermatology clinic, a high proportion of women were diagnosed with exogenous ochronosis compared with men (Hardwick et al., 1989). The low prevalence of exogenous ochronosis in Durban is likely attributable to recent notable South African public health efforts dedicated to eliminating the sale and availability of hydroquinone-containing products on the market.

Of note, women made up 75.8% of the patient sample. Although previously thought to be equal in affecting both sexes, current research shows that pigmentary disorders seem to be more prevalent in women (Amer and Metwalli, 2000; Badreshia-Bansal and Draelos, 2007; Dlova et al., 2012; Dunwell and Rose, 2003; Hermanns et al., 2002; Nesby-O’Dell et al., 2002). In both population and hospital-based studies, Chen et al. (2016) showed that the pooled prevalence of vitiligo was slightly higher in women than in men. In 2014, Hexsel et al. found that melasma has a strong female preponderance with a female-to-male ratio of up to 39:1. Of course, some subcategories of pigmentary disorders, such as PIH from acne keloidalis nuchae, are more common in men than women. However, based on current data, women are more likely to be concerned about pigmentary challenges and/or may be more inclined to pursue consultation and treatment for pigmentary disorders. Thus, women are more likely to be reported in the literature. Further investigation should be sought into sex differences in the epidemiology of pigmentary disorders, particularly within populations with skin of color.

**Conclusion**

The present study documents the spectrum of pigmentary disorders in five major dermatology outpatient public hospital skin clinics in a predominantly female South African patient sample of black and Indian ethnicities. The leading pigmentary disorders in Durban over a 3-month study period include vitiligo, PIH, and melasma. A limitation of this study includes selection bias, because all subjects were clinic patients in a large urban setting, as well as a short study period. As such, our findings cannot be generalized to South Africa as a whole and may not represent the true prevalence of the disease in the population. True community studies and long-term cohort studies are needed to determine the real prevalence of pigmentary disorders in this population and the significant risk factors for these disorders.

A study of pigmentary disorders is important, particularly within populations with skin of color because variances in pigment are much more noticeable in this population group. Knowledge of current pigmentary disorders in KwaZulu-Natal will undoubtedly improve the diagnostic and therapeutic management of patients who reside not only in this province but in South Africa as a whole. The judicious allocation of resources and effective dermatology/public health planning are critical to best serve patients with a particular focus on both prevention and treatment. Finally, an understanding of national and international differences in pigmentary disorders may help provide insights into their pathogenesis.

**Conflict of Interest**

None.

**Funding**

None.

**Study Approval**

The authors confirm that any aspect of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies.

**References**

Abu Share’ah AM, Abdel Dayem H. The incidence of skin diseases in Abu Dhabi (United Arab Emirates). Int J Dermatol 1991;30(2):121–4.
Alakoby OM. Pattern of skin diseases in Eastern Saudi Arabia. Saudi Med J 2005;26(10):1607–10.
Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: A comparative practice survey. Cutis 2007;80(5):387–94.
Amer M, Metwalli M. Topical liquiritin improves melasma. Int J Dermatol 2000;39(4):299–301.
Awoiska O, Burgess CM, Grimes PE. Considerations when treating cosmetic concerns in men of color. Dermatol Surg 2017;43(Suppl. 2):S140–50.
Badreshia-Bansal S, Draelos ZD. Insight into skin lightening cosmeceuticals for women of color. J Drugs Dermatol 2007;6(1):32–9.
Chen T, Grau C, Suprun M, Silverberg NB. Vitiligo patients experience barriers in accessing care. Cutis 2016;98(6):385–8.
Davis EC, Callender VD. Postinflammatory hyperpigmentation: A review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol 2010;3(7):20–31.
Dlova NC, Chateau A, Khoza N, Skoonjane A, Mkhize Z, Katihi OS, et al. Prevalence of skin diseases treated at public referral hospitals in KwaZulu-Natal, South Africa. Br J Dermatol 2015a;173(S2):2–9.
Dlova NC, Hendricks NE, Martinch RM. Skin-lightening creams used in Durban. South Africa Int J Dermatol 2012;51(Suppl. 1):S1–3. 56–9.
Dlova NC, Mankala A, Madala N, Grobler A, Tsoka-Gwegweni J, Hilt RJ. The spectrum of skin diseases in a black population in Durban, KwaZulu-Natal, South Africa. Int J Dermatol 2015b;54(3):279–85.
Doe PT, Asiedu A, Acheampong JW, Rowland Payne CM. Skin diseases in Ghana and the UK. Int J Dermatol 2001;40(5):323–6.
Dunwell P, Rose A. Study of the skin disease spectrum occurring in an Afro-Caribbean population. Int J Dermatol 2003;42(4):287–9.
El-Essawi D, Musial JL, Hammad A, Lim HW. A survey of skin disease and skin-related issues in Arab Americans. J Am Acad Dermatol 2007;56(6):933–8.
Levitt J. The safety of hydroquinone: A dermatologist’s response to the 2006 Federal Register. J Am Acad Dermatol 2007;57(5):854–72.
Nesby-O’Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, Looker AC, et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey, 1988–1994. Am J Clin Nutr 2002;76(1):187–92.
Parthasaradhi A, Al Gufai AF. The pattern of skin diseases in Hail Region, Saudi Arabia. Ann Saudi Med 1998;18(6):558–61.
Sarkar R, Puri P, Jain RK, Singh P, Desai A. Melasma in men: A clinical, aetiological and histological study. J Eur Acad Dermatol Venereol 2010;24(7):768–72.
Vashi NA, Kundu RV. Facial hyperpigmentation: Causes and treatment. Br J Dermatol 2013;169(Suppl. 3):41–56.
Yahya H. Change in pattern of skin disease in Kaduna, north-central Nigeria. Int J Dermatol 2007;46(9):936–43.